Sygnature Discovery

Sygnature Discovery logo

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies. Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography. Sygnature has an enviable track record of success in delivering multiple clinical candidates.

Sygnature's international team of industry-experienced drug researchers (80% with PhDs) are co-located in the same laboratories in Nottingham, UK, to efficiently advance our clients' drug discovery programmes from the laboratory bench towards the clinic. Our unique approach of having medicinal and computational chemists, in vitro biologists and DMPK scientists working side-by-side has delivered 7 clinical compounds (Phases I and II) since 2011. In April 2017, the company will move into its new, purpose-built, fully-enabled research facility, the £30 million "Discovery Building".

Contact Sygnature Discovery via their website

News Archive

09/10/2017   Phoenix Equity Partners announces investment in Sygnature Discovery...more
02/10/2017   Sygnature Discovery forms a strategic alliance with ApconiX...more
27/07/2017   Sygnature Discovery named as Best CRO Finalist in OBN Awards 2017...more
25/07/2017   Sygnature Discovery presented with Queen’s Award for Enterprise 2017...more
28/06/2017   Sygnature Discovery's new HQ is officially open...more
01/06/2017   SelectScience Editorial Article: Insights into Sygnature Discovery...more
16/05/2017   Sygnature Discovery one of London Stock Exchange’s 1000 Companies to Inspire Britain...more
02/05/2017   Sygnature Discovery enhances Biophysics capability...more
21/04/2017   Sygnature Discovery receives a prestigious Queen’s Award for Enterprise...more
07/04/2017   Sygnature Discovery ranked in the Financial Times FT1000f fastest growing companies list...more
30/03/2017   Double celebration for TopiVert and Sygnature Discovery...more
13/03/2017   Sygnature Discovery announces collaboration with Keapstone Therapeutics...more
24/02/2017   Sygnature Discovery in Sunday Times Lloyds SME Export Track 100 for intl. client base...more
01/02/2017   Sygnature Discovery, Mironid, and Peak Proteins to collaborate...more
17/01/2017   Sygnature Discovery announce collaboration with Pelago Bioscience...more

12/10/2016   Sygnature Discovery appoints Ed Browne as Associate Director of DMPK...more
05/10/2016   Sygnature Discovery and Viramatix Announce Anti-Viral Drug Discovery Strategic Alliance...more
21/07/2016   Sygnature Discovery Acquires BMG LABTECH PHERAstar® FSX...more
15/07/2016   Sygnature Discovery Set For Further Growth With Grant From N2 Business Growth Fund...more
04/07/2016   Sygnature Discovery Acquired ImageXpress® Micro Confocal Imaging System...more
16/06/2016   Sygnature Discovery's CEO Wins RSC’s Entrepreneur of the Year Award 2016...more
23/05/2016   Caldan Therapeutics collaborates with Sygnature Discovery...more
15/05/2016   Sygnature Makes Sunday Times Heathrow SME Export Track 100...more
12/05/2016   Caldan Therapeutics Announces Drug Discovery Collaboration with Sygnature Discovery...more
29/04/2016   Topping-out Ceremony for Sygnature's New Discovery Building...more
04/03/2016   Sygnature Discovery to Host Kinase 2016 Event in Nottingham...more
16/02/2016   Sygnature Discovery & RenaSci announce strategic alliance...more
03/02/2016   Sygnature Discovery has delivered 21k+ compounds to European Lead Factory (ELF)...more
30/01/2016   Sygnature Discovery starts 2016 with two key appointments...more
25/01/2016   Sygnature Discovery's group invests in new start up, Peak Proteins...more
10/01/2016   Drug Discovery Today details ELF consortium study featuring Sygnature Discovery...more

08/11/2015   Sygnature will host SCI's 'Young Chemist in Industry'symposium...more
07/10/2015   Ground breaking news for Sygnature Discovery...more
30/07/2015   Sygnature Discovery delivers clinical candidate to Corcept Therapeutics...more
28/07/2015   Sygnature Discovery and Essen BioScience form Strategic Alliance...more
18/05/2015   Sygnature's export growth recognised in national league table...more
07/04/2015   Sygnature Discovery receives French Research accreditation...more
01/02/2015   Sygnature Discovery strengthens team with three key appointments...more

07/12/2014   Sygnature Discovery Welcomes New Associate Director of Bioscience ...more
25/11/2014   Sygnature Discovery Case Study in Creative Quarter publication...more<
19/10/2014   Sygnature Discovery Speaker Summaries published from Aspects of Modern Drug Discovery...more
07/10/2014   Sygnature Celebrates 10 Years of Drug Discovery...more
24/04/2014   New Business Development Director at Sygnature Discovery...more

17/10/2013   Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance...more
14/10/2013   Sygnature Discovery wins Business of the Year Award 2013...more
30/09/2013   Sygnature Discovery appoints new Non-Executive Director...more
23/09/2013   Regional Business Award Success for Sygnature Discovery...more
09/09/2013   Sygnature Discovery selected by CellCentric for prostate cancer programme...more
22/08/2013   Sygnature Discovery finalist in Nottinghamshire’s Best Business Awards...more
24/05/2013   Sygnature Discovery wins Nottingham Post Excellence in Science and Technology Award...more
22/04/2013   Sygnature Discovery provided medicinal chemistry support to new CoCo Therapeutics...more
18/04/2013   Sygnature Discovery selected as Business Awards 2013 finalist ...more
21/03/2013   Sygnature Discovery featured on BBC Radio 4‘s "Today" programme...more
07/02/2013   Sygnature Discovery SME Partner in €196 Million European Lead Factory ...more

30/11/2012   Sygnature Discovery Appoints VP, Business Development North America...more
09/10/2012   BerGenBio selects Sygnature Discovery for BGB002 drug development...more
02/10/2012   The Federated CRO Model: delivering Drug Discovery Expertise...more
15/05/2012   Sygnature Discovery and Pneumolabs Establish Strategic Alliance...more
01/03/2012   National Retrosynthesis Competition ­Sygnature´s Medicinal Chemists are Runners-Up...more
23/01/2012   Sygnature Chemists reach Final in Retrosynthesis Competition ...more
09/01/2012   Sygnature Discovery Nearsourcing article...more

16/12/2011   Sygnature Discovery and Cyprotex Extend Successful Alliance for a Further Two Years ...more
12/12/2011   BioScience Group at Sygnature Discovery is recruiting!...more
05/12/2011   Sygnature Discovery moves into Laboratory #3 ...more
21/11/2011   BBC News Features Sygnature Discovery ...more
31/10/2011   Sygnature Discovery and Saretius Establish Strategic Alliance ...more
06/09/2011   Sygnature Chemical Services becomes Sygnature Discovery...more
08/07/2011   Entrepreneur of the Year Award Winner­ Simon Hirst...more
09/05/2011   Sygnature Founder Simon Hirst finalist in Nottingham Post Entrepreneur Award ...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code